Handelsavisen
prelaunch
Companies Healthcare 087010.KQ
08
087010.KQ KOSDAQ Biotechnology & Medical Research

Peptron Inc

$270 500,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-377,3 %
ROE
-9,7 %
Net margin
-245,3 %
Debt / equity
0,21
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Peptron Inc is a South Korean biotechnology and medical research company that develops and commercializes diagnostic and therapeutic products, primarily in the life sciences tools and services sector.

Business. Peptron Inc (087010.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-9,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 087010.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 087010.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Peptron Inc (087010.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Peptron Inc's capital structure is characterized by a debt-to-equity ratio of 0.21, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 16.45, suggesting strong short-term liquidity. However, the company's cash and equivalents of 4,377,757,820 KRW are insufficient to cover its long-term debt of 29,555,360,280 KRW, resulting in a net cash position that is negative after subtracting total debt.

    Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of 13,823,782,610 KRW and an operating loss of 21,257,384,880 KRW, with a return on equity of -9.73% and a return on assets of -7.72%. These figures indicate a company in distress, with negative returns on both equity and total assets.

    Geographically, Peptron Inc's revenue is concentrated in South Korea, as disclosed in its segments. The company's exposure to a single geographic market increases its vulnerability to local economic and regulatory shifts. No specific segment breakdown is available in the provided data, but the company's primary operations are in the life sciences tools and services sector.

    The company's growth trajectory is negative, with a reported revenue of 5,634,817,680 KRW, significantly below the analyst estimate of 3,120,700,000 KRW. The operating cash flow is negative at -20,586,335,440 KRW, and the free cash flow is also negative at -14,105,420,950 KRW. These figures suggest a lack of operational cash generation and a need for external financing to sustain operations.

    Risk factors include a high probability of liquidity stress, as the company's cash and equivalents are insufficient to cover its long-term obligations. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company has not issued additional shares recently, and there is no indication of near-term dilution pressure. However, the negative operating and free cash flows suggest a potential need for future capital raising, which could lead to dilution.

    Recent events include the company's reported financial results, which show a significant decline in profitability and liquidity. The company's operating cash flow and free cash flow are both negative, indicating a need for external financing. No recent filings or transcripts are available in the provided data, but the company's financial performance suggests a challenging operating environment.

    Key takeaways
    • Peptron Inc is experiencing significant financial distress, with large operating and net losses.
    • The company's liquidity is medium, but its cash and equivalents are insufficient to cover long-term debt.
    • Profitability metrics are negative, with a return on equity of -9.73% and a return on assets of -7.72%.
    • The company's revenue is concentrated in South Korea, increasing its exposure to local market risks.
    • The company's growth trajectory is negative, with reported revenue below analyst estimates.
    • The risk assessment indicates a medium liquidity risk and a low dilution risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $270 500,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $142.01B
    Net cash
    -$25.18B
    Current ratio
    16.4
    Debt / equity
    0.2
    ROA
    -7.7%
    ROE
    -9.7%
    Cash conversion
    149.0%
    CapEx / revenue
    -53.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-377,2 %Below median
    Net Margin-245,3 %Below median
    ROE-9,7 %Above median
    Capex / Rev-53,2 %Bottom quartile
    D/E0,21Bottom quartile
    Cash Conv1,49Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Peptron Inc Market data — financials · 2026-05-26
    • Peptron Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    087010.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage